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Introduction
Indeterminate thyroid nodules on cytology represent a 
challenge for both clinicians and pathologists. Clinicians 
consider all thyroid fine-needle aspiration results that do not 
give a definitive (clearly benign or clearly malignant) result as 
“indeterminate”. Moreover, the new WHO classification of 
endocrine organs introduced a new concept in encapsulated 
follicular patterned lesions on histology (1). The absence, 
questionable and presence of vascular/capsular invasion and 
the absence, questionable and presence of papillary-like 
nuclear features also give rise to different entities according 
to the possible combination of these features. All these new 
entities do not carry the definition of carcinoma in their 
name anymore, but that of “Tumor of uncertain malignant 
potential” divided into “Follicular tumor of uncertain 
malignant potential (FT-UMP), “Well-differentiated 
tumor of uncertain malignant potential” (WDT-UMP) 
and “Non-invasive follicular thyroid neoplasm with 
papillary-like nuclear features” (NIFTP), thus increasing 
the confusion (1). Pathologists are discordant as to what 
an “indeterminate” cytological diagnosis really represents. 
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Some include the atypia of undetermined significance 
or follicular lesion of undetermined significance (AUS/
FLUS), the follicular neoplasm or suspicious for a follicular 
neoplasm (FN/SFN) and the suspicious for malignancy 
(SM) diagnostic categories (DC) (or the THY3 and 
THY4 in the English classification) in this group, while 
others only include the AUS/FLUS and FN/SFN DC (or 
THY3) (2,3). In this review, we consider “indeterminate 
lesions” to be only those cases with an AUS/FLUS or FN/
SFN (or THY3) diagnosis. The SM DC carries a risk of 
malignancy (ROM) in our hands of 60–75%, that justify 
the need for surgery and in our opinion does not allow a 
classification into “indeterminate lesion” (2). Epidemiology, 
ultrasonographic, cytological and molecular features useful 
in refining the ROM and the management of indeterminate 
cytological diagnosis will be reviewed in this article. 
Epidemiology 
The frequency of indeterminate nodules varies greatly in 
literature (4). For the AUS/FLUS DC, frequencies varying 
from 3% to 27.2% with an overall value of 9.6% have 
been reported, while cases in the FN/SFN DC ranged 
from 1.2% to 25.3% with an overall value of 10.1%. The 
overall incidence for indeterminate nodules is around 
19.7% of all thyroid fine-needle aspiration cytology 
(FNAC). The prevalence of WDT-UMP and FT-UMP 
has been reported as having wide variations by the WHO 
blue book, 0.5% to 8.1% and 0.6% to 7.6%, respectively. 
For NIFTP, the reference paper states a prevalence of 
18.6%, but lower values have been recorded in Canada 
(prevalence of 2.1%) and in Asia (2.9%) (1,5-7). In our 
opinion, the introduction of the NIFTP entity will cause a 
further increase in the incidence of indeterminate thyroid 
nodules in FNAC specimens in the future. We have already 
observed an increase of the overall incidence of thyroid 
cancers, especially for the small and indolent papillary 
microcarcinomas (8). Better access to health services and 
the advent of new diagnostic and more performant tools, 
primarily ultrasonography and imaging techniques, have 
been advocated as a major cause in increasing incidence (8). 
Clinically, we are now capable to detect smaller and even 
more deeply located lesions. In the United States, thyroid 
cancer incidence has increased by 3.6% per year on average, 
while incidence-based mortality increased 1.1% per year (9). 
Cytological features
The cytological features of the indeterminate category 
can be roughly divided into four different scenarios: the 
scenario of qualitatively unsatisfactory specimens, the 
scenario of cytologic atypia (mostly nuclear atypia), the 
scenario of architectural atypia (microfollicular architecture) 
and the scenario of combined cytologic and architectural 
atypia (2,10,11).
(I) The first scenario comprises all those specimens 
that suffer from preparation, fixation, and staining 
artifacts and that do not allow a complete evaluation 
of cellular details. Cells appear with nuclear 
enlargement that raise the suspicion for atypia, 
but a definitive diagnosis cannot be established. 
Also, specimens with poor cellularity and somehow 
atypical cells are placed into these scenarios. Atypia 
do not suggest the presence of any specific tumor 
type in particular (like in the two other scenarios) 
and can be epithelial, mesenchymal or lymphoid 
in origin or be non-specific. The cytopathological 
diagnosis would be AUS/FLUS in these cases 
(Figure 1);
(II) The second scenario comprises specimens with 
cytological atypia, irrespective of the architecture 
of the cells. Usually specimens present with few 
cells with enlarged nuclei, chromatin pallor, 
sometimes grooves or vaguely nuclear vacuolization 
(mimicking nuclear pseudoinclusions). Atypical 
cells are so few that exclusion of malignancy as well 
as confirmation of malignancy [in the presence of 
Figure 1 A badly fixed and hemorrhagic smear containing few 
cells whose nuclear details are not fully appreciable and chromatin 
appears poorly stained and clearer than usual. Repetition of the 
aspirate is preferable (Papanicolaou staining, 200×). 
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papillary thyroid cancer (PTC)] is not possible. 
The presence of isolated oncocytes, without a 
clinical context that justifies their presence (i.e., 
Hashimoto’s thyroiditis), is also regarded as 
atypical. The cytopathological diagnosis would be 
AUS/FLUS in these cases (Figure 2);
(III) The third scenario comprises specimens that 
contain microfollicular structures without nuclear 
atypia. If the specimen is poorly cellular and 
shows some microfollicles, a follicular neoplasm 
cannot be completely excluded. Moreover, some 
cases are clearly benign clinically, but have a 
microfollicular component that cannot be ignored. 
The cytopathological diagnosis would be AUS/
FLUS in these cases (Figure 3). Conversely, if 
microfollicles are abundant and do not leave doubt 
concerning the presence of a follicular lesion, the 
cytopathological diagnosis would be FN/SFN 
in these cases. Also, specimens with abundant 
oncocytes, without any colloid or lymphocytic 
infiltration in the background, will be interpreted 
as FN/SFN, Hurthle cell type; 
(IV) The fourth scenario comprises cases with scant 
cellularity and presence of both nuclear atypia and 
microfollicular structures. The cytopathological 
diagnosis would be AUS/FLUS in these cases; 
most cases of NIFTP will be diagnosed within this 
scenario (12). 
Cytology is considered a screening test in the two 
Bethesda DC of AUS/FLUS and FN/SFN, as it cannot 
be conclusive concerning a benign or malignant diagnosis. 
Conversely, cytology in the benign and the malignant DC 
is considered a diagnostic test, because negative predictive 
value (NPV) and positive predictive value (PPV) are high 
and close to 100%, respectively. 
The NIFTP entity and its impact on the 
indeterminate DC
The NIFTP term was introduced in 2016 after an 
international multidisciplinary group of endocrine experts 
conducted a retrospective study confirming what had 
already been known for years; the encapsulated forms 
of follicular variant (FV)-PTC have indolent behavior 
with almost no adverse outcomes (5). Therefore, they 
proposed to treat such neoplasms with a simple lobectomy 
and no adjunct radioiodine radiation and/or completion 
thyroidectomy. The NIFTP concept was accepted and 
included into the latest version of the WHO classification 
of tumors of endocrine organs and endorsed by the 
American Thyroid Association (ATA) (1,13). The revised 
version of TBSRTC also took into account its presence, 
but did not create a specific DC for it, as NIFTP diagnosis 
is not possible on FNA (14). It is possible to suggest its 
presence, and to differentiate it partly from follicular 
adenoma (FA) and classical PTC. However, a definitive 
diagnosis can only be achieved by complete histological 
examination and inclusion in totality of the tumor capsule, 
in order to exclude capsular and vascular invasion and by 
complete histological examination of the lesion content, in 
Figure 2 Another poorly fixed smear with nuclei that are enlarged, 
elongated and that present some optically empty spaces in the 
nucleus (inset) raising the suspicion of a nuclear pseudo-inclusion. 
A papillary thyroid carcinoma could not be completely excluded. 
This sample represents cytological atypia and carries a higher risk 
of malignancy than all other AUS/FLUS scenarios. Patient will 
better benefit of repeated aspiration or molecular test (Papanicolaou 
staining, 200×).
Figure 3 An example of architectural atypia in a poorly cellular 
specimen with fixation artifact, containing some microfollicular 
structures (Papanicolaou staining, 100×). The rest of the samples 
contains abundant colloid and macrofollicular structures.
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order to exclude the presence of papillary structures (15,16). 
After the introduction of the NIFTP lesion and in order 
to avoid false positive diagnoses, i.e., to diagnose tumors 
lesions as malignant that are ultimately considered having 
a low malignant potential, the revised version of TBSRTC 
recommended to use strict criteria to diagnose PTC on 
FNAC, i.e., only in cases with papillary structures, abundant 
nuclear inclusions and psammoma bodies (2,14). The 
disadvantage of this recommendation is that, unfortunately, 
the indeterminate DC will increase in percentage compared 
to the other DC, as we want to avoid a false PTC diagnosis. 
It has been shown by several retrospective studies and in 
a recent meta-analysis, that the great majority of NIFTP 
cases actually fall into the AUS/FLUS DC, followed by the 
FN/SFN DC (12,17-19). In our opinion, the suggestion 
to limit the number of AUS/FLUS cases to 10% will be 
outdated.
Sonographic aspects 
It is well known that thyroid ultrasound (US) cannot be 
confidently used to predict benignity nor malignancy 
of thyroid nodules, thus excluding its sole use in the 
management of patients with thyroid lesions. However, 
thyroid US is a valid tool in the malignant risk stratification 
of indeterminate thyroid nodules along with clinical features 
of patients. Some US features such as microcalcifications, 
hypoechogenicity, irregular margins or absent halo signs, a 
solid aspect, intranodular vascularization, and shape (taller 
than wide), when present together, can predict malignancy 
with a reasonable amount of certainty (13,20). Thus, the 
ATA sonographic patterns should be used not only to set 
the size-threshold for the biopsy but also to personalize the 
management after the biopsy (13,21). To implement the 
PPV of thyroid US, US examination should be extended to 
the central and latero-cervical lymph node compartment 
when thyroid nodules are evaluated, as suspected lymph 
nodes may push the global evaluation of a single nodule 
towards malignancy.
In a recent study of 342 patients diagnosed with AUS/
FLUS during a 4-year period and with histological 
examinations available, the authors aimed to find some 
US features that could help predict malignancy in this 
indeterminate DC. To reflect how badly this DC was 
perceived, the authors of the study defined it as the 
“frustrating” DC (22). Actually, the ATA guidelines have 
suggested that US assessment of suspicious features 
can be a valid tool in the management of patients in 
the indeterminate DC (13). The authors found that 
hypervascularity was the most common suspicious US 
finding in patients with malignancy at histology (22). On 
the contrary, border irregularity was the most common 
US finding in patients with benignity at histology. Many 
other studies have on the contrary showed that other US 
characteristics were able to predict malignancy in the 
AUS/FLUS DC: microcalcifications, “taller than wide” 
diameter on transverse view, border irregularity, absence 
of halo and hypoechogenicity (23-25). Another technique, 
with great expectations in the past to be more effective in 
the evaluation of thyroid nodules, was elastography. This 
technique is based on the deformation characteristic of soft 
tissue when compressed by an external force. This distortion 
is achieved with an US beam and can be registered (26). 
Unfortunately, its use was not as successful as first thought. 
Management
In the first version of TBSRTC, cases diagnosed as AUS/
FLUS are supposed to be managed with repeat FNAC, while 
cases diagnosed as FN/SFN are supposed to be managed 
with diagnostic lobectomy (27). When dealing with poorly 
cellulated, poorly fixed and poorly stained smears, it is better 
to repeat the FNAC to obtain more cellular specimens and 
thus clarify the situation. Repetition of the FNAC in AUS/
FLUS cases could establish a final diagnosis of benignity 
in greater than 50% of nodules (28,29). In the new version 
of TBSRTC, the possibility of a diagnostic lobectomy was 
introduced also for cases diagnosed as AUS/FLUS (2). In 
a study conducted prior to the new version of TBSRTC, it 
was shown that the ROM in cases with a diagnosis of AUS/
FLUS sent directly to surgery was 15.7% and the decision 
for surgery appeared to be influenced by gender and age, 
not US characteristics (30). A recent article from The 
Brigham & Women’s Hospital showed that some patient-
specific factors (i.e., contralateral nodules, hypothyroidism, 
fluorodeoxyglucose avidity on positron emission tomography 
scan, family history of thyroid cancer, and increased surgical 
risk) were associated with a preference by surgeons and 
patients for initial total thyroidectomy in case of cytological 
indeterminate nodules (31). 
Factors that help further in stratifying the ROM of 
patients with indeterminate thyroid nodules and that 
can positively influence the decision to perform surgery, 
comprise a nodule size >4 cm, male sex, age of patients 
at the extremes, and prior head and neck irradiation (32). 
A meta-analysis performed on 3,494 patients with 
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indeterminate thyroid nodules at FNAC calculated the odds 
ratio (OR) for gender and lesion diameter as a risk factor 
of malignancy. The authors found that the pooled OR for 
the male gender was 1.51, whereas the pooled OR for the 
female gender was 0.68; concerning nodule size, the pooled 
OR for nodule size >4 cm was 2.10, whereas the pooled 
OR for a size <4 cm was 0.48 (33). Conversely, a negative 
18F-fluorodeoxyglucose positron emission tomography-
computed tomography (18F-FDG-PET/CT) correctly 
predicted benignity on histopathology and can thus help 
avoid surgery due to its high NPV (34). An additional 
management option suggested in the revised version of 
TBSRTC is the possibility to perform molecular tests for 
patients diagnosed either with the AUS/FLUS DC or with 
the FN/SFN DC (2). 
Molecular alterations
Discovery of any molecular alterations associated with 
thyroid cancer and the consequent implementation of 
molecular tests with such new markers, serve to refine 
the ROM associated with the indeterminate category 
with the benefit of patient management. Two different 
approaches characterize thyroid molecular tests. One aims 
to exclude (rule-out) and the other aims to confirm (rule-in) 
malignancy in the indeterminate category. It is important 
in both cases to know the prevalence of malignancy in 
AUS/FLUS and FN/SFN thyroid nodules at the respective 
institutions before the interpretation of the results, as 
prevalence affects sensitivity and the NPV of the test. 
The rule out test is offered by the Veracyte company and 
consists in the evaluation of several mRNA to optimize 
NPV and is called Afirma gene expression classifier 
(GEC). The rule-in test is developed by the University 
of Pittsburg and commercialized by CBLPath and known 
as ThyroSeq. It is based on next generation sequencing 
(NGS) for point mutations and gene fusions in known 
thyroid cancer related genes. Another test available and 
belonging to the rule-in tests is the ThyGenX-ThyraMIR 
commercialized by Interpace Diagnostics. It is also based 
on NGS for point mutations and gene fusions (ThyGenX) 
plus a panel of microRNA markers (ThyraMIR). Recently, 
new versions of the Afirma [genomic sequencing classifiers 
(GSC)] and ThyroSeq (ThyroSeq V3 Genomic Classifier) 
tests became available and both tests are now associated 
with higher diagnostic accuracy. The new and improved 
version of the Afirma GSC gives values of sensitivity of 
91.1% and specificity of 68.3%, with an improvement of 
36% for specificity in comparison to the previous version 
and with a cancer prevalence of 24% (35). The ThyroSeq 
V3 Genomic Classifier, showed high specificity and PPV 
allowing for diagnostic surgery to be avoided in more than 
60% of patients with indeterminate results on FNAC. The 
prevalence of malignancy in this cohort was 30% and also 
comprises cases diagnosed as SM. In Bethesda nodules 
diagnosed as AUS/FLUS and FN/SFN, ThyroSeq V3 had a 
sensitivity of 94%, specificity of 82%, an NPV of 97%, and 
PPV of 66% with a prevalence of malignancy of 28% (36).
A different possibility to the application of commercially 
available molecular tests is to choose a test in function of 
the cytopathological features. This “personalized” approach 
saves money and takes into account the fact that usually 
cases placed into the AUS/FLUS DC are compromised 
either in terms of quantity or quality. If the predominant 
cytological features are atypical nuclei, then we would prefer 
to look for BRAF, H-N-K-RAS, RET/PTC alterations. On 
the contrary, if the predominant cytological features are 
the presence of non-atypical microfollicular structures, 
then we would prefer to look for H-N-K-RAS and PAX8/
PPARg alterations (11). A recent meta-analysis found a 
BRAF mutation rate of 4–6% in indeterminate cytology (37). 
Thus, our “personalized”, cytopathologically driven 
approach could make BRAF genetic analysis more cost-
effective in nodules with indeterminate cytology.
From a practical point of view, all kind of cytological 
specimens, preparations [including liquid-based cytology 
(LBC)], and all kinds of staining, can be successfully used 
to carry out molecular tests in the thyroid. FNAC provide 
good quality DNA. Even RNA based tests are feasible on 
stained material that can be analyzed for the detection of 
point mutations, chromosomal rearrangements (also with 
FISH), gene expression profiling, and miRNA profiling (38). 
The application of molecular tests should not be 
conceived as a stand-alone test, but rather it should be 
considered as a relevant information to be integrated with 
the clinical and imaging data as an adjunct to patient’s 
management. If the indication for surgery is made a priori 
and independently of the molecular test results, for example 
because of the size of the nodule, it is not useful or cost 
effective to proceed with molecular tests (39). 
Conclusions
In conclusion, the indeterminate cytological diagnosis, 
represented by cases in the AUS/FLUS and FN/SFN 
DC, comprises cases that do not fulfill the cytological 
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criteria to be placed in a malignant category. The ROM 
is about 6–18% and 10–40% if NIFTP is not considered 
a carcinoma and 10–30% and 25–40% if NIFTP is 
considered a carcinoma, respectively. Evaluation of the 
patient’s history, ultrasonographic features, and results of 
molecular tests can help refine the ROM in this group of 
patients and better tailor management for each of them. 
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